TY - JOUR
T1 - Creating a European Health Data Space: Obstacles in Four Key Legal Areas
AU - Kiseleva, Anastasiya
AU - De Hert, Paul
PY - 2021/6/4
Y1 - 2021/6/4
N2 - The creation of the European health data space is one of the core actions promoted by the European Commission in its EU Data Strategy. This task is challenging due to technical, organisational, economic issues that require different measures. This paper focuses on the issues in the legal field and identifies four key legal areas where the creation of a European health data space may face obstacles. These areas are: 1) rules on the provision of healthcare in the Member States; 2) protection of personal data in healthcare provision and medical research; 3) control and use of non-personal data and 4) the regulatory framework on AI. The article analyses and compares these areas and provides a systemised view on causes and consequences. The article concludes with an outlook further legislatives developments related to the European health data space.
AB - The creation of the European health data space is one of the core actions promoted by the European Commission in its EU Data Strategy. This task is challenging due to technical, organisational, economic issues that require different measures. This paper focuses on the issues in the legal field and identifies four key legal areas where the creation of a European health data space may face obstacles. These areas are: 1) rules on the provision of healthcare in the Member States; 2) protection of personal data in healthcare provision and medical research; 3) control and use of non-personal data and 4) the regulatory framework on AI. The article analyses and compares these areas and provides a systemised view on causes and consequences. The article concludes with an outlook further legislatives developments related to the European health data space.
UR - http://dx.doi.org/10.21552/eplr/2021/1/5
UR - http://www.scopus.com/inward/record.url?scp=85117458507&partnerID=8YFLogxK
U2 - 10.21552/eplr/2021/1/5
DO - 10.21552/eplr/2021/1/5
M3 - Article
VL - 5
SP - 21
EP - 36
JO - European Pharmaceutical Law Review
JF - European Pharmaceutical Law Review
SN - 2511-7157
IS - 1
ER -